Provider Profile:
Ira Winer, M.D., Ph.D.
Back to Results
Are you the Physician? Update Profile
Ira Winer, M.D., Ph.D.
Specialties
Oncology - Gynecologic, Oncology - Surgical
Board Certification
American Board of Obstetrics and Gynecology; Gynecologic Oncology
Multidisciplinary Team
Gynecologic Oncology
Phase I Clinical-Pharmacology Program
Locations
Karmanos Cancer Center
4100 John R Street
Detroit, MI 48201
Get Directions
Phone:
1-800-KARMANOS
Call For Appointment
Watch Video
Cancers Treated
Locations
Education
Clinical Trials
Additional Info
Awards
Publications
Cancers Treatments
Cancers Treated
Back to top
Cervical Cancer
Fallopian Tube Cancer
Gestational Trophoblastic Disease
Ovarian Cancer
Uterine (Endometrial) Cancer
Vaginal Cancer
Vulvar Cancer
Locations
Locations
Back to top
Karmanos Cancer Center
4100 John R Street
Detroit, MI 48201
Get Directions
Phone:
1-800-KARMANOS
Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center
31995 Northwestern Highway
Farmington Hills, MI 48334
Get Directions
Get Directions
Get Directions
Education
Education
Back to top
School
University of Michigan Medical School
Residency
University of Michigan Hospitals and Health Centers
Fellowships
Wayne State University School of Medicine
Cancers Treatments
Clinical Trials
Back to top
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Cancer Category
Gynecologic
Age Group
Adult
Phase
NA
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophosectomy to Reduce the Risk of Ovarian Cancer among BRCA1 Carriers [SOROCk]
Cancer Category
Gynecologic
Age Group
Adult
Phase
NA
A Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Cancer Category
Breast,Gastrointestinal (GI),Gynecologic,Lung
Age Group
Adult
Phase
Phase I
A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer
Cancer Category
Gynecologic
Age Group
Adult
Phase
Phase II
Phase 1/2 Study of REGN5668 (MUC16 X CD28, A Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3)
Cancer Category
Gynecologic
Age Group
Adult
Phase
Phase I/II
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer
Cancer Category
Gynecologic
Age Group
Adult
Phase
Phase I
Phase II Study of ONC201 Plus Weekly Paclitaxel in Patients with Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Category
Gynecologic
Age Group
Adult
Phase
Phase II
A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Cancer Category
Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Lung,Neurological
Age Group
Adult
Phase
Phase I
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Cancer Category
Gastrointestinal (GI),Genitourinary (GU),Other
Age Group
Adult
Phase
Phase I
A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - ARTISTRY-1
Cancer Category
Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Lung,Skin
Age Group
Adult
Phase
Phase I/II
Additional Info
Additional Info
Back to top
Related Videos
Meet Dr. Ira S. Winer - Gynecologic Oncology
Watch the Video
Awards
Awards
Back to top
Awards
2019 Hour Detroit Top Docs
2014 1st prize Research, Annual Wayne Day Presentation
2012 1st Prize in Fellow Research. Michigan Section ACOG Research Day oral presentation
Graduated Cum Laude with MD, PhD and Distinction in research from University of Michigan Medical School
Graduated Summa Cum Laude with Honors and Distinction in Major from Boston University
Member of Phi Beta Kappa and Golden Key Honor Societies
Professional Memberships
American College of Obstetrics
Gynecology Society of Gynecologic Oncology
Publications
Publications
Back to top
Significance of lymphovascular space invasion in Uterine Serous Carcinoma- Extent or Presence? Int J Gynecol Pathol. 2015 Jan;34(1):47-56. PMID: 25473753 Winer I, Ahmed QF, Mert I, Bandyopadhyay S, Cote M, Munkarah AR, Hussein Y, Al-Wahab Z, Elshaikh MA, Alosh B, Schultz DS, Mahdi H, Nucci MR, Van de Vijver KK, Morris RT, Oliva E, Ali-Fehmi R.
The prognostic significance of histologic type in early cervical cancer- A multi-Institutional Study. Gynecol Oncol. 2015 Jun;137(3):474-8. Epub 2015 Feb 10. PMID: 25677061Winer I, Alvarado-Cabrero I, Hassan O, Ahmed, QF, Alosh B, Bandyopadhyay S, Thomas S, Albayrak A, Talukdar S, Al-Wahab Z, Elshaikh M, Munkarah A, Morris R, Ali-Fehmi R.
Correlation of tumor size with other prognostic factors in uterine serous carcinoma: a large multi-institutional study. Gynecol Oncol. 2013 Feb;128(2):316-21. PMID: 23138135Winer I, Mahdi H, Bandyopadhyay S, Semaan A, Van de Vijver KK, Nucci MR, Abdul-Karim F, Hussein Y, Qureshi F, Hayek K, Alosh B, Schulz D, Cote M, Munkarah A, Morris R, Oliva E, Ali-Fehmi R.
Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Cancer Metastasis Rev. 2015 Jan 18. PMID: 25597035Seward SM, Winer I.
F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res. 2010 Nov 1;70(21):8674-83. PMID: 20959470 Winer I, Wang S, Lee YE, Fan W, Gong Y, Burgos-Ojeda D, Spahlinger G, Kopelman R, Buckanovich RJ.
Loading...